FDA Drug recall D-0040-2025
Ascorbic Acid Inj
- FDA Drug
- Class I
- terminated
- Published 2024-11-13
On 2024-11-13 the FDA classified a Class I recall of Ascorbic Acid Inj by Staska Pharmaceuticals, citing presence of Particulate Matter: Presence of glass particulates.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0040-2025 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2024-09-30 |
| Published | 2024-11-13 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Staska Pharmaceuticals |
| Distribution | US |
Product
Ascorbic Acid Inj. Solution, 25,000mg/50mL (500mg/mL), 50mL single use vial, Rx only, Staska Pharmaceuticals, 742 Evergreen Drive, Bennet, NE 68317
Reason
Presence of Particulate Matter: Presence of glass particulates.
Identifiers
| code_info | Lot #SP2400058, Exp 12/31/2024 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0040-2025%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.